clinical trial · NCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Muscle-Invasive Bladder CarcinomaGastroesophageal AdenocarcinomaSynthetic long peptide personalized cancer vaccinePoly ICLCSignatera assay
brief summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
started
Mar 20, 2025
primary completion
Oct 31, 2028
completion
Mar 31, 2033
last updated
Jan 13, 2026
official title
Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol